;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AIT Austrian Institute of Technology, BioVendor, Scienion deal

    AIT Austrian Institute of Technology GmbH, Vienna, Austria BioVendor Laboratorni medicina A.S., Karasek, Czech Republic Scienion AG, Berlin, Germany Business: Diagnostic AIT Austrian Institute of Technology, BioVendor …

    Published on 10/27/2014
  • Ambit, Daiichi Sankyo deal

    Ambit Biosciences Corp. (NASDAQ:AMBI), San Diego, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer Daiichi Sankyo began its tender offer to acquire Ambit Biosciences for up to $19.50 per share,…

    Published on 10/27/2014
  • Bavarian Nordic, J&J deal

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Bavarian Nordic granted the Johnson & Johnson's Crucell Holland B.V. exclusive, worldwide rights…

    Published on 10/27/2014
  • BioMotiv, Takeda deal

    BioMotiv LLC, Cleveland, Ohio Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cardiovascular, Endocrine/Metabolic, Inflammation BioMotiv granted Takeda exclusive rights to programs sourced by …

    Published on 10/27/2014
  • Chindex International, Shanghai Fosun Pharmaceutical, TPG Capital deal

    Chindex International Inc., Bethesda, Md. Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196;HKSE:2196), Shanghai, China TPG Capital, Fort Worth, Texas Business: Other Shanghai Fosun, private investment firm …

    Published on 10/27/2014
  • Civitas, Acorda deal

    Civitas Therapeutics Inc., Chelsea, Mass. Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Business: Neurology Neurological disorder company Acorda completed its acquisition of Civitas for $525 million in cash (see…

    Published on 10/27/2014
  • Compugen, Bayer deal

    Compugen Ltd. (NASDAQ:CGEN;Tel Aviv:CGEN), Tel Aviv, Israel Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer Compugen received a $6 million milestone payment under an August 2013 deal with Bayer to research …

    Published on 10/27/2014
  • Eisai, Kyorin deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Infectious Eisai granted Kyorin rights to evaluate the feasibility of developing antibacterial compounds …

    Published on 10/27/2014
  • EKF Diagnostics, Massachusetts General Hospital deal

    EKF Diagnostics Holdings plc (LSE:EKF), Penarth, U.K. Massachusetts General Hospital, Boston, Mass. Business: Diagnostic, Cancer Under a two-year deal, the hospital will use EKF's PointMan DNA enrichment assays to …

    Published on 10/27/2014
  • Enanta, AbbVie deal

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious Enanta announced it will not exercise its option to co-develop HCV candidate ABT-493 in the U.S. …

    Published on 10/27/2014
  • Enanta, AbbVie deal

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious Enanta and AbbVie amended the royalty structure on worldwide net sales of regimens containing ABT-…

    Published on 10/27/2014
  • Forendo Pharma, Apricus Biosciences deal

    Forendo Pharma Oy, Turku, Finland Apricus Biosciences Inc. (NASDAQ:APRI), San Diego, Calif. Business: Endocrine/Metabolic Forendo granted Apricus exclusive, U.S. rights to develop and commercialize fispemifene, which …

    Published on 10/27/2014
  • H. Lee Moffitt Cancer Center, Forma Therapeutics deal

    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla. Forma Therapeutics Holdings LLC, Watertown, Mass. Business: Cancer The institute granted Forma an exclusive option to license exclusive, worldwide rights …

    Published on 10/27/2014
  • Monash University, GlaxoSmithKline deal

    Monash University, Victoria, Australia GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Hematology Monash granted GlaxoSmithKline a license to develop a heat-stable and low-cost inhaled form of oxytocin to…

    Published on 10/27/2014
  • NewLink, Genentech, Roche deal

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer NewLink granted Roche's Genentech Inc. unit exclusive, …

    Published on 10/27/2014
  • Rockefeller University, NeoStem deal

    Rockefeller University, New York, N.Y. NeoStem Inc. (NASDAQ:NBS), New York, N.Y. Business: Gene/Cell therapy The university granted NeoStem exclusive rights to patents covering the use of dendritic cell immunotherapies.…

    Published on 10/27/2014
  • Sage Labs, Horizon Discovery deal

    Sage Labs Inc., St. Louis, Mo. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Business: Functional genomics Horizon acquired Sage Labs for $48 million comprised of $16 million in cash and $32 million in Horizon …

    Published on 10/27/2014
  • Sanofi, Immune Design deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Business: Infectious Sanofi's Sanofi Pasteur vaccines division partnered with Immune Design to develop a therapy to treat …

    Published on 10/27/2014
  • Shire, AbbVie deal

    Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Pharmaceuticals The companies mutually terminated a July 18 proposal by AbbVie to acquire Shire for L31.4 billion ($53.8 …

    Published on 10/27/2014
  • Sutro, Celgene deal

    Sutro Biopharma Inc., South San Francisco, Calif. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Sutro granted Celgene an exclusive, ex-U.S. license to develop and commercialize cancer immunotherapies using …

    Published on 10/27/2014
  • TesoRx Pharma, Aspen deal

    TesoRx Pharma LLC, Menlo Park, Calif. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Endocrine/Metabolic TesoRx Pharma granted Aspen Pharmacare's Aspen Global Inc. subsidiary exclusive rights …

    Published on 10/27/2014
  • University of Technology, Sydney, Nuvilex deal

    University of Technology, Sydney, Nuvilex Inc. (OTCQB:NVLX), Silver Spring, Md. Business: Endocrine/Metabolic The university granted Nuvilex exclusive, worldwide rights to develop and commercialize human insulin-…

    Published on 10/27/2014
  • Vernalis, RedoxTherapeutics deal

    Vernalis plc (LSE:VER), Winnersh, U.K. RedoxTherapeutics Inc., Boston, Mass. Business: Cancer Vernalis granted RedoxTherapeutics exclusive, worldwide rights to develop and commercialize vipadenant (V2006) for immuno-…

    Published on 10/27/2014
  • Zymeworks, Eli Lilly deal

    Zymeworks Inc., Vancouver, B.C. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Antibodies Eli Lilly and Zymeworks expanded a January deal to use Zymeworks' Azymetric technology to develop and commercialize …

    Published on 10/27/2014
  • Aduro BioTech, J&J deal

    Aduro BioTech Inc., Berkeley, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Aduro granted Johnson & Johnson's Janssen Biotech Inc. subsidiary exclusive, worldwide rights to lung cancer …

    Published on 10/20/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993